Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycovax-002 phase 1 in healthy adults
NCT05799651Phase 1Active, not recruiting
- Sponsor
- Glycovax Pharma
- Start
- Apr 2023
- Primary completion
- Jun 2024
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Glycovax-002 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Glycovax Pharma. Primary endpoint: Overall Safety and Reactogenicity. Started Apr 2023; status: active, not recruiting.
02
Drugs
Glycovax-002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05799651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799651.